Tris Pharmaceutical CEO Discusses Strategies for Maximizing Drug Impact
Ketan Mehta, founder and CEO of Tris Pharmaceutical, discussed the company's evolution and strategies for enhancing drug efficacy in an interview with Pharmaceutical Executive. Initially focused on oral technology, Tris has expanded its scope to include pain management and addiction treatments. Mehta highlighted specific challenges in existing therapies, such as the sudden crash in drug levels seen in ADHD medications, which negatively affects patient quality of life. To address this, Tris employs a dual delivery system utilizing tiny particles that leverage the body's natural mechanisms to ensure continuous, sustained relief throughout the day. This approach aims to provide consistent symptom control without the need for booster doses. Additionally, Mehta described the benefits of liquid formulations, which allow for precise calibration of dosages. This flexibility is particularly valuable at the start of therapy when optimal doses are unknown, enabling patients to adjust intake based on individual needs. The interview underscores Tris Pharmaceutical's commitment to adapting drug delivery methods to improve patient outcomes and navigate diverse regulatory environments effectively.
Wire timeline
Tris Pharmaceutical CEO Discusses Strategies for Maximizing Drug Impact
Ketan Mehta, founder and CEO of Tris Pharmaceutical, discussed the company's evolution and strategies for enhancing drug efficacy in an interview with Pharmaceutical Executive. Initially focused on oral technology, Tris has expanded its scope to include pain management and addiction treatments. Mehta highlighted specific challenges in existing therapies, such as the sudden crash in drug levels seen in ADHD medications, which negatively affects patient quality of life. To address this, Tris employs a dual delivery system utilizing tiny particles that leverage the body's natural mechanisms to ensure continuous, sustained relief throughout the day. This approach aims to provide consistent symptom control without the need for booster doses. Additionally, Mehta described the benefits of liquid formulations, which allow for precise calibration of dosages. This flexibility is particularly valuable at the start of therapy when optimal doses are unknown, enabling patients to adjust intake based on individual needs. The interview underscores Tris Pharmaceutical's commitment to adapting drug delivery methods to improve patient outcomes and navigate diverse regulatory environments effectively.
PharmExec articles